ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024

Contributed by: Business Wire

Logo

Tags

Research

Infectious Diseases

Clinical Trials

Biotechnology

AIDS

Health

Pharmaceutical

General Health

Science

Apretude

More Like This

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV